NCT00539773已完成不适用
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 主要终点
- Efficacy
研究概览
简要总结
Phase II Trial of concurrent administration of intravesical BCG & Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with superficial transitional carcinoma of the urinary bladder
排除标准
- 未提供
结局指标
主要结局
Efficacy
时间窗: overall
次要结局
未报告次要终点
研究者
Dr. Naeem A. Chaudhri
Principal Investigator
King Faisal Specialist Hospital & Research Center
相似试验
已完成
2 期
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder CancerBladder CancerNCT00004122Roswell Park Cancer Institute
尚未招募
1 期
A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder CancerBladder CancerNCT06255964SUNHO（China）BioPharmaceutical CO., Ltd.236
已完成
2 期
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of BladderBladder NeoplasmsNCT00343356LanZhou University138
Unknown
1 期
Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)Chronic Hepatitis BNCT01589952Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh20
已完成
2 期
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinHepatitis CNCT01309932Bristol-Myers Squibb165